Al Hammadi Holding Releases Results for the Six-month Period Ended 30 June 2026

3 August 2026, Riyadh (Saudi Arabia). Al Hammadi Holding announces its financial results for the quarter and six-month period ended 30 June 2026 (Q2 2026 and 1H 2026). The Company reported first-half revenues of SAR 641 million, up 7% year-on-year (y-o-y) increase. Net profit reached SAR 128 million, marking a 6% y-o-y decline, while the net profit margin (NPM) narrowed to 20.0% from 22.6% in 1H 2025, mainly reflecting lower gross profitability coupled with higher SG&A expenses and increased finance costs during the period. On a quarterly basis, revenues increased 8% y-o-y to SAR 322 million in Q2 2026, supporting a 16% y-o-y increase in quarterly net profit to SAR 72 million, with the net margin expanding to 22.3% from 20.8% in Q2 2025. The quarterly earnings improvement was supported by a SAR 9 million reversal of expected credit losses, compared with a SAR 11 million charge in the comparable quarter, along with the recognition of a non-recurring SAR 7 million gain arising from compensation for the partial expropriation of the Group's Al Munsiyah land affected by Riyadh road development works.

Key Financial and Operational Highlights

Financial Highlights (SAR mn)	**Q2 2025**	**Q2 2026**	***Y-o-Y Change***	**1H 2025**	**1H 2026**	***Y-o-Y Change***
Total Revenues	298.2	321.7	*7.9%*	600.1	640.8	*6.8%*
Cost of Revenue	(205.2)	(241.8)	*17.8%*	(410.6)	(459.8)	*12.0%*
Gross Profit	**93.0**	**79.9**	***(14.0%)***	**189.5**	**181.0**	***(4.5%)***
GPM	*31.2%*	*24.8%*	*(6.3pts)*	*31.6%*	*28.2%*	*(3.3pts)*
Operating Profit	**63.9**	**69.5**	***8.8%***	**140.6**	**122.1**	***(13.2%)***
Operating Profit Margin	*21.4%*	*21.6%*	*0.2pts*	*23.4%*	*19.1%*	*(4.4pts)*
Net Profit	**62.0**	**71.9**	***16.0%***	**135.9**	**128.1**	***(5.7%)***
NPM	*20.8%*	*22.3%*	*1.6pts*	*22.6%*	*20.0%*	*(2.7pts)*
Operational Highlights ('000)						
Inpatient Volumes	11.2	9.9	*(11.6%)*	*22.5*	19.7	*(12.2%)*
Outpatient Volumes	239.1	233.5	*(2.3%)*	489.7	451.4	*(7.8%)*

- Al Hammadi reported **total revenues** of SAR 641 million during the first half of 2026, marking a robust 7% y-o-y increase, supported by growth across both medical services and pharmaceuticals, which rose 3% and 21% y-o-y, respectively. Medical services revenue growth was primarily driven by a 4% y-o-y increase at Al Suwaidi Hospital, alongside a 2% increase at Al Nuzha Hospital. This growth was achieved despite lower patient volumes across both facilities, as higher average revenue per patient, supported by the Group's pricing and service-mix optimization strategy, more than offset the decline in patient activity. In the pharmaceutical segment, top-line growth was mainly driven by Pharma Serve, whose revenue more than doubled to SAR 55 million from SAR 24 million in 1H 2025, reflecting continued expansion of its customer base following its decision to extend its services to private sector clients earlier in 2025, alongside improved product mix.

- On a quarterly basis, Al Hammadi reported revenues of SAR 322 million in Q2 2026, up 8% y-o-y. Growth was supported by a 4% y-o-y increase in medical services revenue to SAR 250 million and a 24% y-o-y rise in pharmaceutical revenue to SAR 72 million. Medical services revenue increased despite patient volumes remaining below prior-year levels, as higher average revenue per patient offset softer activity, while pharmaceutical growth was driven by Pharma Serve, whose revenue more than doubled y-o-y to SAR 26 million. On a quarter-on-quarter basis, Group revenue increased by a modest 1%, as the recovery in outpatient activity and in-house pharmacy sales was partly offset by a softer inpatient case mix and lower Pharma Serve sales due to the timing of customer orders following higher purchases in Q1 2026.
- **Net profit** stood at SAR 128 million in 1H 2026, down 6% y-o-y, with NPM narrowing to 20.0% from 22.6% in 1H 2025. The decline reflected weaker gross profitability, as cost of revenue increased 12% y-o-y and outpaced top-line growth, resulting in a 4% decline in gross profit. Net profitability was further weighed by a 33% increase in SG&A expenses to SAR 67 million and a 23% rise in finance costs to SAR 15 million. These pressures were partially offset by higher contributions from associates, lower expected credit loss provisions, and the recognition of a non-recurring SAR 7 million gain related to compensation for the partial expropriation of the Group's land in Al Munsiyah district.
- On a quarterly basis, net profit increased 16% y-o-y to SAR 72 million in Q2 2026, with the NPM expanding to 22.3% from 20.8% in Q2 2025. The improvement was primarily driven by a SAR 9 million reversal of expected credit losses, compared with an SAR 11 million charge in the prior-year quarter, alongside the aforementioned non-recurring SAR 7 million gain. Higher contributions from associates, which doubled y-o-y to SAR 15 million, provided further support to bottom-line growth.
- **Net debt to equity** recorded 5.9% as of 30 June 2026, compared to a net debt to equity ratio of 2.3% recorded as of 31 December 2025.
- **Inpatient admissions** totaled 19.7 thousand in 1H 2026, down 12% y-o-y, reflecting a 9% decline at Al Nuzha Hospital and an 18% decrease at Al Suwaidi Hospital. Despite the lower volumes, inpatient revenue grew 7% y-o-y, reflecting continued progress under the Group's pricing and service-mix optimization strategy. In Q2 2026, inpatient admissions reached 9.9 thousand, down 12% y-o-y but broadly stable q-o-q. As admissions typically follow the previous quarter's outpatient activity, Q2 inpatient volumes continued to reflect the softer Q1 base associated with Ramadan and Eid.
- **Outpatient visits** reached 451.4 thousand in 1H 2026, down 8% y-o-y, as volumes declined 5% at Al Nuzha and 12% at Al Suwaidi. Outpatient revenue inched down 1% y-o-y despite the slowdown in visits, as it was supported by a 7% y-o-y increase in average revenue per outpatient visit. In Q2 2026, outpatient visits reached 233.5 thousand, down 2% y-o-y but up 7% q-o-q, with Al Nuzha and Al Suwaidi up by 9% and 4% q-o-q, respectively, versus Q1 2026. The quarterly recovery reflects a normalization in patient activity following the seasonal softness associated with Ramadan and Eid at the start of the year.

Management Comment

As we reach the mid-point of 2026, Al Hammadi Holding has continued to deliver top-line growth while advancing the strategic investments and initiatives required to fuel the next phase of the Group's growth. First-half revenues increased 7% year-on-year to SAR 641 million, while second-quarter revenues grew 8% to SAR 322 million. This growth was achieved despite patient volumes remaining below the prior-year level, reflecting the more resilient revenue base per patient established through the pricing and service-mix optimization initiatives implemented under Phase 1 of our multi-year growth strategy, alongside continued expansion across our pharmaceuticals business.

Operationally, the second quarter marked an encouraging step forward. As the seasonal pressures associated with Ramadan and Eid dissipated, outpatient visits recovered 7% quarter-on-quarter, while inpatient admissions stabilized. Although patient activity has not yet fully returned to prior-year levels, the sequential improvement indicates that volumes are beginning to normalize following the seasonally softer first quarter. Our focus under Phase 2 is to build on this trajectory by accelerating patient volumes, strengthening utilization across both hospitals, and translating our higher-value revenue base into stronger and more sustainable growth.

From a profitability standpoint, net profit reached SAR 128 million in the first half, with the net profit margin standing at 20.0%. The year-on-year moderation primarily reflected lower gross profitability, alongside higher operating expenses and finance costs as we continued to invest in specialized medical talent, marketing, and the broader capabilities required to support future growth. Meanwhile, second-quarter net profit increased 16% year-on-year to SAR 72 million, supported by the reversal of expected credit losses and a non-recurring gain related to compensation for the partial expropriation of the Group's land in Al Munsiyah. Our focus for the remainder of the year is to sustain the recovery in patient activity and translate it into stronger operating leverage and improved underlying profitability.

Beyond our core hospital operations, our pharmaceuticals segment maintained its strong momentum, recording 21% revenue growth during the first half. Pharma Serve remained the principal driver of this performance, with sales more than doubling year-on-year as the business continued to expand its private-sector customer base. Sudair Pharmaceuticals also continued to strengthen its contribution to the Group. The steady operation of the first phase of its insulin production line supported a marked improvement in performance, with revenue reaching SAR 219 million and net profit reaching SAR 74 million in 1H 2026, compared with SAR 158 million and SAR 35 million, respectively, in the prior-year period. Meanwhile, construction of the second phase continued to progress, supporting Sudair's long-term growth potential and its role within our expanding pharmaceutical platform.

We are also beginning to see tangible contributions from our investment in Wareed Medical Company, which has been contributing to the Group's cash flows since the first quarter. Wareed recorded revenue of SAR 88 million and net profit of SAR 13 million during the first half, compared with SAR 38 million and SAR 3 million, respectively, in 1H 2025. Through its diagnostics, homecare and mobile healthcare services, Wareed extends our reach beyond traditional hospital-based care and enhances our ability to provide more accessible and integrated patient services.

In parallel, our strategic cooperation with AC Milan is progressing towards implementation, with the specialized sports medicine and rehabilitation center established under the partnership scheduled to commence operations during the first half of September 2026. By combining AC Milan's international medical expertise with Al Hammadi's clinical platform in Riyadh, we aim to develop differentiated services in sports medicine, rehabilitation, and performance-related care. This partnership complements our continued recruitment of specialized physicians and supports our broader ambition to expand into higher-value clinical specialties.

Our capacity-expansion program remains central to Phase 2 of our growth strategy. Construction at the Olaya facility continues to progress towards its planned relaunch in the first half of 2027, while preparations for the Group's longer-term developments at Al Narjis and Al Munsiyah remain underway. Our M&A pipeline is intended to substantially expand our capacity and extend Al Hammadi's presence across strategic and underserved areas of Riyadh's healthcare market.

As we enter the second half of 2026, our priorities are clear: sustain the recovery in patient activity, improve utilization across our existing network, maintain disciplined cost management, and continue executing our expansion and revenue diversification plans. With a stronger revenue base per patient, a growing presence across pharmaceuticals and adjacent healthcare services, and a clear capacity-development roadmap, we believe Al Hammadi is well positioned to capture the Kingdom's expanding demand for premium, integrated healthcare while creating sustainable long-term value for all our stakeholders.

Mohammad S. Al Hammadi
Chief Executive Officer

Consolidated Analysis





Financial Review

Revenue Analysis

Al Hammadi posted total revenues of SAR 641 million in 1H 2026, up 7% y-o-y, reflecting growth across both medical services and pharmaceuticals, which increased 3% and 21% y-o-y, respectively. Medical services revenue grew despite lower patient volumes, supported by higher revenue base per patient following the Group's pricing and service-mix optimization initiatives. Pharmaceutical growth was primarily driven by Pharma Serve, whose sales more than doubled year-on-year during the six-month period.

On a quarterly basis, revenues increased 8% y-o-y and 1% q-o-q to SAR 322 million in Q2 2026. The year-on-year increase reflected 4% growth in medical services revenue and a 24% rise in pharmaceutical revenue, while the quarter-on-quarter improvement was supported by the normalization in patient activity following the seasonal slowdown in Q1 2026.

Medical Services (77% of total revenue in 1H 2026)

Medical services, which include inpatient and outpatient operations at Al Nuzha and Al Suwaidi hospitals, generated revenue of SAR 497 million in 1H 2026, up 3% y-o-y. The segment accounted for 77% of the Company's consolidated top-line, compared with 80% in 1H 2025. In Q2 2026, medical services revenue increased 4% y-o-y and 1% q-o-q to SAR 250 million.

- On a **hospital basis**, Al Nuzha recorded a 2% y-o-y increase in revenue during 1H 2026 to SAR 293 million, while Al Suwaidi delivered 4% growth to SAR 203 million. Both hospitals achieved revenue growth despite lower inpatient and outpatient volumes, reflecting the effectiveness of the Group's pricing and service-mix optimization strategy. In Q2 2026, revenue increased 4% y-o-y at both hospitals. Compared to the previous quarter, Al Nuzha's revenue rose 2%, while Al Suwaidi's revenue remained broadly stable at SAR 101 million.
- On a **payor** basis, cash and direct-company revenue increased 15% y-o-y during 1H 2026, supported by continued traction from the recruitment of specialized physicians and the Group's growing focus on higher-value procedures. MoH revenue rose 23% y-o-y, reflecting increased referrals of complex cases to private healthcare providers. Meanwhile, insurance revenue declined 4% amid the slowdown in patient activity. On a quarterly basis, direct-

Al Hammadi Holding

company revenue increased 6% q-o-q, while insurance revenue recovered 2% q-o-q and MoH revenue declined 4% q-o-q.

- Finally, on a **patient-segment basis**, inpatient revenue increased 7% y-o-y to SAR 274 million in 1H 2026, as the higher revenue base per admission more than offset lower inpatient volumes. Outpatient revenue declined marginally by 1% y-o-y to SAR 222 million, with higher average revenue per visit largely offsetting the decline in outpatient activity as well. In Q2 2026, inpatient revenue increased 7% y-o-y to SAR 136 million, while outpatient revenue remained broadly stable at SAR 114 million.

Medical Services Revenue Breakdown (1H 2026)



Medical Services Revenue by Patient Type (1H 2026)



Pharmaceutical Services (23% of total revenue in 1H 2026)

Al Hammadi's pharmaceutical sales contributed 23% of consolidated revenue in 1H 2026, recording SAR 144 million, up 21% y-o-y. The Group's in-house pharmacies generated sales of SAR 89 million, down 7% y-o-y, mainly reflecting the lower outpatient activity associated with the first-quarter seasonal pressures. Meanwhile, Pharma Serve's sales more than doubled to SAR 55 million from SAR 24 million in 1H 2025, reflecting the continued expansion of its private-sector customer base following the strategic decision taken in early 2025 to broaden its commercial reach.

During Q2 2026, pharmaceutical revenue increased 24% y-o-y to SAR 72 million. Pharma Serve remained the principal growth driver, with sales more than doubling to SAR 26 million, while in-house pharmacy revenue increased 1% y-o-y to SAR 46 million.

Cost of Revenue

Al Hammadi's cost of revenue stood at SAR 460 million in 1H 2026, up 12% y-o-y from SAR 411 million in 1H 2025. As a share of total revenue, cost of revenue increased to 72% from 68% in the prior-year period. The increase mainly reflected higher medical staff salaries, driven by planned compensation adjustments and continued recruitment of specialized physicians, alongside higher maintenance costs. These investments support the Group's efforts to strengthen its clinical capabilities and expand its offering of complex procedures.

On a quarterly basis, cost of revenue increased 18% y-o-y to SAR 242 million in Q2 2026, due to a 10% y-o-y increase in medical staff salaries coupled with higher maintenance costs. Consequently, cost of revenue as a percentage of revenue increased to 75% from 69% in Q2 2025.



Gross Profit

Gross profit recorded SAR 181 million in 1H 2026, down 4% y-o-y, with the gross profit margin narrowing to 28.2% from 31.6% in 1H 2025. Gross profitability was pressured by the 12% y-o-y increase in cost of revenue, which outpaced top-line growth, reflecting higher medical staff salaries, maintenance costs, and continued investment in the Group's operating and clinical capabilities.

On a quarterly basis, gross profit declined 14% y-o-y to SAR 80 million in Q2 2026, with the gross profit margin narrowing to 24.8% from 31.2% in Q2 2025. The contraction reflected similar cost dynamics, as the 18% y-o-y increase in cost of revenue outpaced the 8% y-o-y growth in revenue during the quarter. Gross profitability was additionally impacted by a non-recurring SAR 8 million revenue adjustment arising from the settlement of claims with insurance providers.

Sales, general & administrative (SG&A)

SG&A expenses reached SAR 67 million in 1H 2026, up 33% y-o-y from SAR 51 million in 1H 2025. As a share of revenue, SG&A expenses increased to 11% from 8% in the prior-year period. The increase was primarily driven by selling and marketing expenses, which expanded to SAR 14 million, reflecting campaigns associated with the Group's rebranding initiatives and strategic partnership with AC Milan. General and administrative expenses also increased 15% y-o-y to SAR 53 million.

On a quarterly basis, SG&A expenses increased 24% y-o-y to SAR 30 million in Q2 2026. Sequentially, however, SG&A expenses declined 17% q-o-q from SAR 37 million in Q1 2026, primarily reflecting the normalization of marketing expenditure following the elevated spending associated with the Group's rebranding and partnership initiatives during the previous quarter.

Operating Profit

Operating profit declined 13% y-o-y to SAR 122 million in 1H 2026, compared with SAR 141 million in 1H 2025, while the operating profit margin narrowed to 19.1% from 23.4%. The decline primarily reflected weaker gross profitability and the 33% y-o-y increase in SG&A expenses. These pressures were partially offset by lower expected credit loss provisions of SAR 8 million, compared with SAR 11 million in the prior-year period, alongside the recognition of a non-recurring SAR 7 million gain related to compensation for the partial expropriation of the Group's land in Al Munsiyah.

During Q2 2026, operating profit increased 9% y-o-y to SAR 70 million, with the operating profit margin at 21.6%. The improvement was primarily driven by a faster collection pace from key clients, which supported a SAR 9 million reversal of expected credit losses, compared with an SAR 11 million charge in Q2 2025, alongside the aforementioned non-recurring gain.Compared to Q1 2026, operating profit increased 32% q-o-q while the operating margin expanded from 16.5% to 21.6%, largely reflecting the same factors.

Net Profit

Net Profit, Margin (SAR mn, %)



Net profit stood at SAR 128 million in 1H 2026, down 6% y-o-y from SAR 136 million in 1H 2025, with the net profit margin narrowing to 20.0% from 22.6%. The decline largely mirrored the trends observed at the operating-profit level and was further weighed by higher finance costs during the period attributable to accelerated construction work at the Group's Al Olaya. These pressures were partially offset by the Group's share of profit from associates, which more than doubled to SAR 29 million from SAR 13 million, supported by the continued ramp-up of SPC's insulin production line.

On a quarterly basis, net profit increased 16% y-o-y to SAR 72 million in Q2 2026, with the net profit margin expanding to 22.3% from 20.8% in Q2 2025. The improvement reflected the improvement in operating profit, supported by the reversal of expected credit losses and the non-recurring gain related to compensation for the partial expropriation of the Group's land in Al Munsiyah, alongside higher contributions from associates. Compared to the previous quarter, net profit increased 28% q-o-q, with the net profit margin expanding to 22.3% from 17.6% in Q1 2026, largely reflecting the same factors.

Dividend Payments

Al Hammadi adheres to a clear **dividend** policy of distributing no less than 60% of annual net profits on a quarterly basis to shareholders. During 1H 2026, the company declared cash dividends of SAR 64 million for the quarters Q4 2025 and Q1 2026. Subsequent to the period end, the Board of Directors approved a cash dividend of SAR 0.27 per share (SAR 43.2 million) for the second quarter of 2026.

Balance Sheet Highlights

Al Hammadi's **total assets** stood at SAR 2,886 million as of 30 June 2026, compared with SAR 2,735 million as of 31 December 2025. Inventories increased to SAR 112 million from SAR 84 million over the same period.

Cash and cash equivalents booked SAR 40 million as of 30 June 2026, down from SAR 128 million as of 31 December 2025, reflecting higher capital expenditure, investment in Wareed Medical, and dividend payments. The Company's current and quick ratios stood at 2.8 and 2.4 as of 30 June 2026, respectively, versus 3.0 and 2.7 as of year-end 2025.

The Company recorded **total debt** of SAR 162 million as of 30 June 2026, down from SAR 175 million at year-end 2025. Total debt remains entirely comprised of interest-free government loans. Meanwhile, **net debt** increased to SAR 122 million from SAR 47 million as of 31 December 2025, primarily reflecting the decline in cash balances during the period.

Shareholders' equity stood at SAR 2,067 million as of 30 June 2026, up from SAR 2,005 million as of 31 December 2025. The Company's debt-to-equity ratio declined to 7.8% from 8.7% at year-end 2025. Meanwhile, net debt-to-equity increased to 5.9% from 2.3%, reflecting the decline in cash balances during the period.

Operational Review





Inpatient Volumes

On a Group level, Al Hammadi recorded 19.7 thousand inpatient admissions in 1H 2026, down 12% y-o-y. Inpatient volumes declined 9% y-o-y at Al Nuzha and 18% y-o-y at Al Suwaidi, reflecting the seasonal weakness recorded during Q1 2026, while activity remained below the prior-year level in Q2. Al Nuzha accounted for 63% of total inpatient admissions, up from 61% in 1H 2025, while Al Suwaidi contributed the remaining 37%, compared with 39% previously. In Q2 2026, inpatient admissions reached 9.9 thousand, down 12% y-o-y but broadly stable q-o-q. The limited q-o-q recovery reflects the typical one quarter lag between outpatient activity and inpatient admissions, as Q2 2026 volumes continued to bear the impact of softer activity associated with Ramadan and Eid in Q1 2026.

Outpatient Volumes

Al Hammadi recorded 451.4 thousand outpatient visits in 1H 2026, down 8% y-o-y, reflecting a 5% y-o-y decline at Al Nuzha and a 12% y-o-y decrease at Al Suwaidi. Average revenue per visit increased 7% y-o-y, supported by the Group's pricing and service-mix optimization strategy. In Q2 2026, outpatient visits reached 233.5 thousand, down 2% y-o-y but up 7% q-o-q, reflecting a recovery in patient activity following the seasonally weaker first quarter. Al Nuzha accounted for 65% of total outpatient visits in 1H 2026, up from 63% in 1H 2025, while Al Suwaidi's contribution declined to 35% from 37% in 1H 2025.

Utilization

During 1H 2026, average inpatient utilization stood at 90% at Al Nuzha and 100% at Al Suwaidi across its 210 operational beds, unchanged from the prior-year period. Outpatient utilization reached 85% at Al Nuzha and 80% at Al Suwaidi, compared with 90% at both facilities in 1H 2025. Within the second quarter, activity was strong in April and remained healthy through most of May before moderating around Eid al-Adha, while June was affected by the start of the summer holiday period.

Sudair Pharma Company (SPC)

SPC, a leading pharmaceutical manufacturer in which Al Hammadi holds a 35% stake, continued to build on its operational progress during the first half of 2026. The company, which has focused on oncology medications since 2021, officially launched the first phase of its insulin production line earlier in 2025, with operations now running steadily and contributing meaningfully to the Group's results. SPC reported revenue of SAR 219 million in 1H 2026, up from SAR 158 million in 1H 2025, while net profit increased to SAR 74 million from SAR 35 million, underscoring its growing role as a second growth pillar for the Group. Construction of the second phase, which will include full insulin refilling capabilities, commenced in February 2025 and is expected to be completed within the next four years. In parallel, SPC continues to expand its therapeutic offering with new respiratory-focused medicines, supporting its ambition of becoming a leading player in Saudi Arabia's pharmaceutical manufacturing sector.

Capacity Expansions

On the **capacity expansion front**, Al Hammadi continues to advance its short- and long-term growth plans. In the **near term**, the Group has expanded capacity to 600 rooms and 220 clinics across its two facilities.

In parallel, Al Hammadi is advancing its **long-term** growth strategy, aiming to launch three new facilities by 2030. More specifically, construction work at the Olaya facility officially began in June 2025, with the relaunch scheduled for the first half of 2027. Olaya will house 200 inpatient rooms and 120 clinics, as well as two centers of excellence specializing in sports medicine and orthopedics. In addition, the Group's fourth facility (Al Munsiyah) will feature 200 new inpatient rooms and 120 new clinics and will enable the Group to tap into North Riyadh's underserved market. Construction is expected to commence following the receipt of final approvals and certifications. Finally, Al Narjis hospital is slated for inauguration in the first quarter of 2030 and will also house 200 inpatient rooms, 120 clinics, and two centers of excellence specializing in oncology and plastic surgery. Construction work at Al Narjis is scheduled to begin later in 2027 and be completed in around 30 months. These expansions will see the Group more than double its bed capacity within the coming five years, strengthening the Company's market position in Riyadh's competitive healthcare market. CAPEX expenditures to fuel the Group's growth strategy are projected at around SAR 900 million by 2030, subject to regulatory approvals and project timelines, with approximately 50% of the planned CAPEX to be financed through debt.

– End –

Consolidated Income Statement

SAR mn	Q2 2025	Q2 2026	*Y-o-Y Change*	1H 2025	1H 2026	*Y-o-Y Change*
Revenue	**298.2**	**321.7**	***7.9%***	**600.1**	**640.8**	***6.8%***
Cost of revenue	(205.2)	(241.8)	*17.8%*	(410.6)	(459.8)	*12.0%*
Gross Profit	**93.0**	**79.9**	***(14.0%)***	**189.5**	**181.0**	***(4.5%)***
GPM	*31.2%*	*24.8%*	*(6.3pts)*	*31.6%*	*28.2%*	*(3.3pts)*
Selling and marketing expenses	(2.1)	(3.4)	*63.2%*	(4.6)	(14.4)	*215.9%*
Administrative and general expenses	(22.5)	(27.0)	*19.9%*	(46.1)	(52.9)	*14.7%*
Expected credit loss provision	(10.9)	9.2	*(184.0%)*	(10.6)	(8.1)	*(23.0%)*
Gain on disposal of property, plant and equipment	-	7.0	*-*	-	7.0	*-*
Other operating income	6.4	3.9	*(39.6%)*	12.4	9.5	*(23.1%)*
Operating Profit	**63.9**	**69.5**	***8.8%***	**140.6**	**122.1**	***(13.2%)***
Operating profit margin	*21.4%*	*21.6%*	*0.2pts*	*23.4%*	*19.1%*	*(4.4pts)*
Share of profit in associates	7.1	14.7	*108.1%*	12.5	29.2	*133.1%*
Finance income	1.1	-	*-*	3.1	-	*-*
Finance costs	(6.1)	(8.3)	*37.8%*	(12.4)	(15.2)	*22.9%*
Net profit before Zakat	**66.0**	**75.9**	***15.0%***	**143.9**	**136.1**	***(5.4%)***
Zakat expenses	(4.0)	(4.0)	*-*	(8.0)	(8.0)	*-*
Net profit for the period	**62.0**	**71.9**	***16.0%***	**135.9**	**128.1**	***(5.7%)***
NPM	*20.8%*	*22.3%*	*1.6pts*	*22.6%*	*20.0%*	*(2.7pts)*
	-	-		-	-	
Earnings per share:	0.39	0.45	*16.0%*	0.85	0.80	*(5.7%)*

Consolidated Balance Sheet

SAR mn	31 December 2025	30 June 2026
ASSETS		
Non-current assets		
Property and equipment	1,715.7	1,680.2
Intangible assets and goodwill	25.6	24.6
Investment in associates	159.2	284.7
Total non-current assets	**1,900.5**	**1,989.6**
Current Assets		
Inventories	84.0	111.8
Other receivables	7.4	87.3
Prepayments	62.1	67.3
Contract assets	13.6	15.0
Trade receivables	539.5	575.4
Cash and cash equivalents	127.9	40.0
Total current assets	**834.6**	**896.7**
TOTAL ASSETS	**2,735.0**	**2,886.3**
SHAREHOLDER'S EQUITY AND LIABILITIES		
SHAREHOLDER'S EQUITY		
Share capital	1,600.0	1,600.0
General reserve	101.2	101.2
Retained earnings	303.9	365.4
TOTAL SHAREHOLDER'S EQUITY	**2,005.2**	**2,066.6**
LIABILITIES		
Non-current liabilities		
Loans	156.0	143.1
Government grants	91.5	88.3
Lease liabilities	95.8	92.2
Contingent consideration payable	-	59.7
Employees' terminal benefits	105.7	115.7
Total non-current liabilities	**449.0**	**499.0**
Current liabilities		
Loans	18.7	18.7
Government grants	6.5	6.5
Lease liabilities	15.9	17.1
Contingent consideration payable	-	20.0
Accrued zakat	16.5	8.7
Trade payables	83.8	76.6
Accrued expenses	47.3	53.4
Other payables	22.8	24.0
Contract liabilities	69.4	95.5
Total current liabilities	**280.8**	**320.6**
TOTAL LIABILITIES	**729.9**	**819.6**
TOTAL SHAREHOLDER'S EQUITY AND LIABILITIES	**2,735.0**	**2,886.3**

Consolidated Statement of Cash Flow

SAR mn	30 June 2025	30 June 2026
OPERATING ACTIVITIES		
Net profit	**135.9**	**128.1**
Adjustments to reconcile net profit to cash flow		
Depreciation of property and equipment	47.7	40.3
Amortization of intangible assets	0.3	1.1
Gain on disposals of property and equipment	-	(7.0)
Company share of profits from associate	(12.5)	(29.2)
Provision for expected credit losses	10.6	8.1
Government grants released	(4.6)	(3.2)
Current services cost of employees' terminal benefits	6.2	9.1
Contract liability generated during the period	27.8	34.6
Finance income	(3.1)	-
Finance cost	12.4	15.2
Zakat charge during the period	8.0	8.0
	228.6	205.1
Working capital adjustments		
Inventories	(6.7)	(27.7)
Other debit balances	(1.5)	(0.1)
Prepayments	(4.4)	(5.0)
Trade receivables	(50.9)	(41.2)
Contract assets	(2.5)	(4.4)
Due from (to) related parties- net	(0.0)	(0.0)
Accounts payable	(10.9)	(7.2)
Accrued expenses	(9.5)	6.2
Other credit balances	0.1	1.1
Contract liability	(11.1)	(8.6)
Employees' terminal benefits paid	(4.8)	(4.2)
Zakat paid	(15.5)	(15.7)
Net cash flows generated from operating activities	**110.8**	**98.2**
Cash flows from investing activities		
Purchase of property and equipment	(25.7)	(75.0)
Purchase of intangible assets	(0.8)	(0.2)
Investment in associate	-	(20.2)
Dividends received from associate	-	1.1
Finance income received	2.6	-
Net cash flows (used in) investing activities	**(23.9)**	**(94.3)**
Cash flows from financing activities		
Proceed from short-term borrowings	-	90.0
Repayment of bank & government borrowings	(17.3)	(107.3)
Finance charges paid	(1.4)	(2.1)
Lease liability	(8.0)	(8.5)
Dividends paid	(111.9)	(63.9)
Net cash flows (used in) financing activities	**(138.6)**	**(91.8)**
Net change in cash and cash equivalents	(51.7)	(87.9)
Cash and cash equivalents at the beginning of the period	245.3	127.9
Cash and cash equivalents, at end of period	**193.6**	**40.0**

About Al Hammadi Holding

Al Hammadi Holding is an integrated healthcare company and a premier hospital operator in Riyadh providing world-class healthcare services to hundreds of thousands of local and foreign residents each year. The company currently operates two hospitals in the Saudi Arabian capital, housing more than 600 inpatient rooms and 220 outpatient clinics. In line with the company's ambitious growth plans and Saudi Arabia's Vision 2030 strategy, Al Hammadi is aiming to inaugurate three more facilities in Riyadh over the coming five years, more than doubling its inpatient and outpatient capacity. Al Hammadi also offers retail pharmacy services through a network of physical stores and a growing online presence and is also active in the vaccine import segment through its subsidiary, Pharma Serve. Al Hammadi boasts several international accreditations and certificates, including the Canadian Accreditation Certificate (ACCREDITATION CANADA), the Joint Commission International (JCI) accreditation, the Australian Council on Healthcare Standards International (ACHSI), the Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI), the American College of Cardiology (ACC) accreditation, as well as the ISO 9001:2008 certification and the Saudi Heart Association Certificate.

Contact

Investor Relations Department
ir@alhammadi.com